MX2020006812A - Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. - Google Patents
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.Info
- Publication number
- MX2020006812A MX2020006812A MX2020006812A MX2020006812A MX2020006812A MX 2020006812 A MX2020006812 A MX 2020006812A MX 2020006812 A MX2020006812 A MX 2020006812A MX 2020006812 A MX2020006812 A MX 2020006812A MX 2020006812 A MX2020006812 A MX 2020006812A
- Authority
- MX
- Mexico
- Prior art keywords
- degraders
- irak
- irak degraders
- compositions
- methods
- Prior art date
Links
- 239000001064 degrader Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
La presente invención se refiere a compuestos, composiciones de los mismos, y métodos para usar los mismos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610397P | 2017-12-26 | 2017-12-26 | |
US201862653178P | 2018-04-05 | 2018-04-05 | |
US201862694955P | 2018-07-06 | 2018-07-06 | |
US201862712377P | 2018-07-31 | 2018-07-31 | |
PCT/US2018/067304 WO2019133531A1 (en) | 2017-12-26 | 2018-12-21 | Irak degraders and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006812A true MX2020006812A (es) | 2020-11-06 |
Family
ID=66949188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006812A MX2020006812A (es) | 2017-12-26 | 2018-12-21 | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (4) | US10874743B2 (es) |
EP (1) | EP3731869A4 (es) |
JP (2) | JP2021508703A (es) |
CN (1) | CN112105385A (es) |
AU (1) | AU2018396142A1 (es) |
BR (1) | BR112020012997A2 (es) |
CA (1) | CA3086763A1 (es) |
IL (2) | IL304055A (es) |
MX (1) | MX2020006812A (es) |
SG (1) | SG11202005912PA (es) |
WO (1) | WO2019133531A1 (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
CA3076613A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
BR112020012997A2 (pt) | 2017-12-26 | 2020-12-01 | Kymera Therapeutics, Inc. | degradadores de irak e usos dos mesmos |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
WO2019196812A1 (zh) * | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
EP3817822A4 (en) * | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
US11639354B2 (en) | 2018-07-31 | 2023-05-02 | Fimecs, Inc. | Heterocyclic compound |
CA3121667A1 (en) * | 2018-09-30 | 2020-04-02 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
AU2019371400A1 (en) * | 2018-11-02 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Acetylation writer inhibitor development and uses thereof |
US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2020160295A1 (en) | 2019-01-30 | 2020-08-06 | Montelino Therapeutics, Llc | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
BR112021019748A2 (pt) | 2019-04-05 | 2021-12-07 | Kymera Therapeutics Inc | Degradadores de stat e usos dos mesmos |
US20230132715A1 (en) * | 2019-07-17 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
US20220402935A1 (en) | 2019-07-31 | 2022-12-22 | Fimecs, Inc. | Heterocyclic compound |
LT4015513T (lt) * | 2019-09-24 | 2023-12-11 | Shanghai Meiyue Biotech Development Co., Ltd. | Irak inhibitorius ir jo gavimo bei panaudojimo būdas |
US20230125380A1 (en) * | 2019-11-05 | 2023-04-27 | Dermira, Inc. | Topical Compositions Comprising IRAK4 Inhibitors for Use in Treating Dermatological Conditions Characterised by Inflammation |
US20230190940A1 (en) * | 2019-12-10 | 2023-06-22 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
UY38986A (es) | 2019-12-18 | 2021-07-30 | Novartis Ag | Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas |
EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics Inc | SMARCA DEGRADERS AND USES THEREOF |
EP4100004A4 (en) * | 2020-02-03 | 2024-02-28 | Kymera Therapeutics Inc | IRAQ KINASE DEGRADATION AGENTS AND THEIR USES |
WO2021162493A1 (ko) * | 2020-02-14 | 2021-08-19 | 보로노이 주식회사 | 단백질 키나아제 분해 유도 화합물 및 이의 용도 |
CN115335381A (zh) * | 2020-02-19 | 2022-11-11 | 新锐思生物制药股份有限公司 | 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途 |
JP2023517393A (ja) * | 2020-03-17 | 2023-04-25 | メッドシャイン ディスカバリー インコーポレイテッド | タンパク質分解調整剤およびその使用方法 |
TW202200543A (zh) * | 2020-03-19 | 2022-01-01 | 美商凱麥拉醫療公司 | Mdm2降解劑及其用途 |
US20230211008A1 (en) * | 2020-03-31 | 2023-07-06 | Orum Therapeutics, Inc. | Conjugates |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
WO2021222542A1 (en) * | 2020-04-30 | 2021-11-04 | President And Fellows Of Harvard College | 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders |
EP4146660A1 (en) | 2020-05-06 | 2023-03-15 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
EP4153587A1 (en) * | 2020-05-18 | 2023-03-29 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
EP4161521A1 (en) * | 2020-06-03 | 2023-04-12 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
US20230406859A1 (en) | 2020-06-22 | 2023-12-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Methotrexate analogs and methods of use |
US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
MX2023001217A (es) * | 2020-07-30 | 2023-03-03 | Kymera Therapeutics Inc | Metodos de tratamiento de linfomas mutantes. |
WO2022087216A1 (en) * | 2020-10-21 | 2022-04-28 | Kymera Therapeutics, Inc. | Double degraders and uses thereof |
US20230096599A1 (en) * | 2020-12-09 | 2023-03-30 | Kymera Therapeutis, Inc. | Irak degraders and uses thereof |
CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
CN116648248A (zh) * | 2021-01-26 | 2023-08-25 | 成都茵创园医药科技有限公司 | 芳香化合物、含其的药物组合物及其应用 |
EP4291193A1 (en) * | 2021-02-10 | 2023-12-20 | BeiGene Switzerland GmbH | Egfr degraders and methods of use |
JP2024506657A (ja) * | 2021-02-15 | 2024-02-14 | カイメラ セラピューティクス, インコーポレイテッド | Irak4分解剤およびその使用 |
WO2022229466A2 (en) | 2021-04-30 | 2022-11-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Non-covalent halotag ligands |
WO2022236339A1 (en) * | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
CN113549060A (zh) * | 2021-07-28 | 2021-10-26 | 派普医药(江苏)有限公司 | 一种3-氨基-1-(四氢呋喃-2-基氧基)-1h-吡唑-4-甲腈的合成方法 |
US11976071B2 (en) | 2021-08-18 | 2024-05-07 | Gilead Sciences, Inc. | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases |
TW202317097A (zh) * | 2021-09-08 | 2023-05-01 | 大陸商南京明德新藥研發有限公司 | 戊二醯亞胺類化合物與其應用 |
WO2023045978A1 (zh) * | 2021-09-26 | 2023-03-30 | 南京明德新药研发有限公司 | 2,6-哌啶二酮类化合物与其应用 |
CA3236262A1 (en) * | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
WO2023104155A1 (zh) * | 2021-12-08 | 2023-06-15 | 标新生物医药科技(上海)有限公司 | E3泛素连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 |
TW202333670A (zh) * | 2022-01-04 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用 |
CN114213283B (zh) * | 2022-01-04 | 2023-06-02 | 攀枝花学院 | 一锅法制备[2-[1-(Fmoc-氨基)乙氧基]乙氧基]乙酸的方法 |
TW202345827A (zh) * | 2022-01-14 | 2023-12-01 | 美商凱麥拉醫療公司 | Irak4降解物及其用途 |
WO2023180388A1 (en) | 2022-03-24 | 2023-09-28 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs |
WO2023192586A1 (en) * | 2022-03-31 | 2023-10-05 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
CN117157298A (zh) * | 2022-03-31 | 2023-12-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途 |
WO2023201274A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Use of an irak4 modulator for gene therapy |
WO2023201272A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Use of irak4 modulators for gene therapy |
WO2023237049A1 (en) * | 2022-06-09 | 2023-12-14 | Beigene, Ltd. | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use |
CN114843114B (zh) * | 2022-06-30 | 2022-10-25 | 深圳市今朝时代股份有限公司 | 基于氮掺杂的电极材料及其在超级电容器上的应用 |
WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
CN115636815B (zh) * | 2022-10-24 | 2023-10-27 | 新乡学院 | 一种泊马度胺连接脲类化合物的制备方法和应用 |
CN115872877A (zh) * | 2022-12-21 | 2023-03-31 | 南京安伦化工科技有限公司 | 一种氨基四甘醇合成方法 |
Family Cites Families (219)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
US5360811A (en) | 1990-03-13 | 1994-11-01 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents |
JP3545461B2 (ja) | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
EE05351B1 (et) | 1999-12-10 | 2010-10-15 | Pfizer Products Inc. | Prrolo[2,3-d]primidiinhendid |
DE10002509A1 (de) | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
ES2243461T3 (es) | 2000-02-28 | 2005-12-01 | Sugen, Inc. | Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa. |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
WO2002020740A2 (en) | 2000-09-08 | 2002-03-14 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
CA2445395C (en) | 2001-04-27 | 2010-03-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
SI1536827T1 (sl) | 2002-08-14 | 2009-06-30 | Silence Therapeutics Ag | Uporaba protein-kinaze n beta |
JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ, インコーポレイテッド | Pi−3キナーゼインヒビタープロドラッグ |
KR101168441B1 (ko) | 2003-05-30 | 2012-07-25 | 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 | 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법 |
AU2004257167B2 (en) | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
JP4398263B2 (ja) | 2004-01-13 | 2010-01-13 | 富士通株式会社 | 経路設計方法 |
PL3153514T3 (pl) | 2004-05-13 | 2022-01-10 | Icos Corporation | Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
CN101175738B (zh) | 2005-05-12 | 2010-10-27 | 雅培制药有限公司 | 细胞凋亡促进剂 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
DK1931645T3 (da) | 2005-10-07 | 2014-09-29 | Exelixis Inc | N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase |
BR122021011787B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
DK2455382T3 (da) | 2005-12-13 | 2017-01-02 | Incyte Holdings Corp | Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer |
PT1966130E (pt) | 2005-12-23 | 2014-01-30 | Zealand Pharma As | Compostos miméticos de lisina modificados |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
DE602007007323D1 (de) | 2006-04-26 | 2010-08-05 | Hoffmann La Roche | Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
US20100279316A1 (en) * | 2007-01-19 | 2010-11-04 | Leonid Gorelik | Antibodies to Phosphorylated IRAK4 |
KR101737753B1 (ko) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CA2960659C (en) | 2007-11-09 | 2021-07-13 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ido阻害剤 |
EA017218B1 (ru) | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak-киназ |
WO2009132238A2 (en) | 2008-04-24 | 2009-10-29 | Newlink Genetics | Ido inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
LT4209510T (lt) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui |
US8921037B2 (en) | 2008-12-16 | 2014-12-30 | Bo Han | PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair |
CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
RS58693B1 (sr) | 2009-12-10 | 2019-06-28 | Hoffmann La Roche | Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena |
JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス,インコーポレーテッド | B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 csf-1r에 대한 항체 및 이의 용도 |
US8114621B2 (en) | 2010-03-12 | 2012-02-14 | Saladax Biomedical Inc. | Lenalidomide and thalidomide immunoassays |
TWI713942B (zh) | 2010-05-04 | 2020-12-21 | 美商戊瑞治療有限公司 | 與集落刺激因子1受體(csf1r)結合之抗體類 |
WO2012003281A2 (en) | 2010-06-30 | 2012-01-05 | Brandeis University | Small-molecule-targeted protein degradation |
CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
PL2730564T3 (pl) | 2010-11-19 | 2018-09-28 | Ligand Pharmaceuticals Inc. | Heterocykliczne aminy i ich zastosowania |
WO2012078559A2 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
JP5947311B2 (ja) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変t細胞の使用 |
AU2011347711B2 (en) | 2010-12-20 | 2017-02-02 | Merck Serono S.A. | Indazolyl triazole derivatives as IRAK inhibitors |
US8703941B2 (en) | 2011-01-10 | 2014-04-22 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
EP2688872A4 (en) | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
EP2773207B1 (en) | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
CN104582705A (zh) | 2012-01-10 | 2015-04-29 | 林伯士艾瑞斯公司 | 白介素-1受体相关激酶(irak)抑制剂和其用途 |
WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
RU2666530C2 (ru) | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
JP6096219B2 (ja) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物 |
US9242975B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
CA2871445C (en) | 2012-05-11 | 2020-07-07 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
MX2015000129A (es) | 2012-07-10 | 2015-04-14 | Ares Trading Sa | Derivados de pirimidin pirazolilo. |
US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2014011906A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US9085586B2 (en) | 2012-07-11 | 2015-07-21 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
KR20150058222A (ko) | 2012-09-19 | 2015-05-28 | 에프. 호프만-라 로슈 아게 | 2-옥소-2,3,4,5-테트라하이드로-1h-벤조[b]다이아제핀 및 암 치료에서의 이의 용도 |
EP2903617B1 (en) | 2012-10-08 | 2019-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
US9586948B2 (en) | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
JP6204484B2 (ja) * | 2012-11-08 | 2017-09-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物 |
EP2922840B1 (en) * | 2012-11-08 | 2016-12-21 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
MX2015005272A (es) * | 2012-11-08 | 2015-07-14 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa). |
GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
CN104968658B (zh) | 2013-02-07 | 2017-08-01 | 默克专利股份公司 | 哒嗪酮‑酰胺衍生物 |
AU2014214254B2 (en) | 2013-02-07 | 2018-03-29 | Merck Patent Gmbh | Macrocyclic Pyridazinone derivatives |
WO2014143672A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases |
RU2016110852A (ru) | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
UY35821A (es) | 2013-11-08 | 2015-06-30 | Takeda Pharmaceutical | Compuesto heterocíclico |
BR112016008468A2 (pt) | 2013-11-18 | 2017-10-03 | Hoffmann La Roche | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer |
CN110156770B (zh) | 2013-11-27 | 2022-10-04 | 圣诺康生命科学公司 | 作为tam族激酶抑制剂的氨基吡啶衍生物 |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
EA201691401A1 (ru) | 2014-01-10 | 2016-11-30 | Ориджин Дискавери Текнолоджиз Лимитед | Индазольные соединения в качестве ингибиторов irak4 |
DK3805233T3 (da) | 2014-01-13 | 2024-04-15 | Aurigene Oncology Ltd | (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling |
CN106573906A (zh) | 2014-03-17 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 哌啶‑二酮衍生物 |
US9914735B2 (en) | 2014-03-19 | 2018-03-13 | Boehringer Ingelheim International Gmbh | Heteroaryl Syk inhibitors |
HRP20220362T1 (hr) | 2014-04-04 | 2022-05-13 | Pfizer Inc. | Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitori irak4 |
JP6778114B2 (ja) | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
CA2945819A1 (en) | 2014-04-22 | 2015-10-29 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
CN106456609A (zh) | 2014-06-20 | 2017-02-22 | 奥瑞基尼探索技术有限公司 | 作为irak4抑制剂的取代的吲唑化合物 |
ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
TW201613872A (en) | 2014-07-18 | 2016-04-16 | Biogen Ma Inc | IRAK4 inhibiting agents |
US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
WO2016053770A1 (en) | 2014-09-30 | 2016-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
US9932350B2 (en) | 2014-09-30 | 2018-04-03 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
WO2016053771A1 (en) | 2014-09-30 | 2016-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
EP3200788B1 (en) | 2014-09-30 | 2019-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
PT3221306T (pt) | 2014-11-20 | 2020-02-19 | Merck Patent Gmbh | Compostos de heteroarilo como inibidores de irak e utilização dos mesmos |
EP3256470B1 (en) | 2014-12-23 | 2023-07-26 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
US10369252B2 (en) * | 2014-12-23 | 2019-08-06 | South Dakota Board Of Regents | Electrospun three-dimensional nanofibrous scaffolds with interconnected and hierarchically structured pores |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
AU2016209349B2 (en) | 2015-01-20 | 2020-05-07 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the Androgen Receptor |
WO2016144849A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
EP3268004B1 (en) | 2015-03-12 | 2019-12-18 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of irak4 activity |
WO2016144844A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of irak4 activity |
US10329295B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrrolotriazine inhibitors of IRAK4 activity |
US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
EA039043B1 (ru) | 2015-04-22 | 2021-11-25 | Райджел Фармасьютикалз, Инк. | Пиразольные соединения и способ получения и применения данных соединений |
GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
UY36660A (es) | 2015-04-30 | 2016-11-30 | Bayer Pharma AG | Combinaciones de inhibidores de irak4 |
CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
US10618903B2 (en) * | 2015-06-24 | 2020-04-14 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
JP6843775B2 (ja) | 2015-06-24 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロアリール置換のアミノピリジン化合物 |
CN105085620B (zh) | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
MX2018000360A (es) | 2015-07-10 | 2018-06-11 | Arvinas Inc | Moduladores basados en mdm2 de proteolisis y metodos de uso asociados. |
MX2018000471A (es) | 2015-07-13 | 2018-04-10 | Arvinas Inc | Moduladores de proteolisis basados en alanina y metodos de uso asociados. |
KR20180025896A (ko) | 2015-07-15 | 2018-03-09 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak-4 저해제로서 인다졸 및 아자인다졸 화합물 |
US20180208605A1 (en) | 2015-07-15 | 2018-07-26 | Aurigene Discovery Technologies Limited | Substituted Aza Compounds as IRAK-4 Inhibitors |
US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
ES2865199T3 (es) | 2015-08-27 | 2021-10-15 | Pfizer | Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4 |
RU2743360C2 (ru) | 2015-09-18 | 2021-02-17 | Мерк Патент Гмбх | Гетероарильные соединения в качестве ингибиторов irak и их применение |
RU2743716C2 (ru) | 2015-09-18 | 2021-02-24 | Мерк Патент Гмбх | Гетероарильные соединения в качестве ингибиторов irak и их применение |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
MX2018005340A (es) | 2015-11-02 | 2018-05-17 | Univ Yale | Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos. |
JP6895439B2 (ja) | 2015-12-22 | 2021-06-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体 |
US20190016703A1 (en) | 2015-12-30 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
US20200216454A1 (en) | 2015-12-30 | 2020-07-09 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for her3 degradation and methods of use |
EP3405465B1 (en) | 2016-01-20 | 2021-10-13 | Biogen MA Inc. | Irak4 inhibiting agents |
KR102520814B1 (ko) | 2016-03-16 | 2023-04-11 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | 작동자 t 세포 기능 개선을 위한 세레브론에 대한 소분자 |
US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
CA3020275A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Mdm2 protein degraders |
EP3440082A1 (en) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
WO2017201449A1 (en) * | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017207385A1 (de) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
GB201610147D0 (en) * | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
ES2940911T3 (es) | 2016-06-27 | 2023-05-12 | Rigel Pharmaceuticals Inc | Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4 |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
JP2019196309A (ja) | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
WO2018089736A1 (en) | 2016-11-10 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
JP7308146B2 (ja) | 2016-11-22 | 2023-07-13 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | インターロイキン1受容体関連キナーゼの阻害剤およびその使用 |
CN108322937B (zh) | 2017-01-18 | 2020-08-11 | 上海诺基亚贝尔股份有限公司 | 无线接入网中用于网络切片的资源分配方法和编排器 |
MX2019009046A (es) | 2017-01-31 | 2019-10-30 | Arvinas Operations Inc | Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo. |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
SI3621960T1 (sl) | 2017-05-11 | 2021-11-30 | Bristol-Myers Squibb Company | Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji |
CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
CN111278815B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 戊二酰亚胺 |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
CA3076613A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
EP3700901A1 (en) | 2017-10-24 | 2020-09-02 | Genentech, Inc. | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof |
WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
EP3710443A1 (en) * | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
BR112020012997A2 (pt) | 2017-12-26 | 2020-12-01 | Kymera Therapeutics, Inc. | degradadores de irak e usos dos mesmos |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
CA3090275A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
WO2019165229A1 (en) | 2018-02-23 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Small molecules for inducing selective protein degradation and uses thereof |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
WO2020010210A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Mertk degraders and uses thereof |
EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
EP3823613A4 (en) | 2018-07-20 | 2022-05-11 | Dana Farber Cancer Institute, Inc. | DEGRADATION AGENTS TARGETING PROTEINS THROUGH KEAP1 |
US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US20230087825A1 (en) | 2019-06-10 | 2023-03-23 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
WO2020251974A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
WO2020251971A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
WO2020264499A1 (en) | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
WO2020264490A1 (en) | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
WO2021011631A1 (en) | 2019-07-15 | 2021-01-21 | Kymera Therapeutics, Inc. | Fused-glutarimide crbn ligands and uses thereof |
US20230093080A1 (en) | 2019-07-15 | 2023-03-23 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2021011871A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Mertk degraders and uses thereof |
US20230132715A1 (en) | 2019-07-17 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
US20230219945A1 (en) | 2019-12-17 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
-
2018
- 2018-12-21 BR BR112020012997-6A patent/BR112020012997A2/pt unknown
- 2018-12-21 US US16/230,792 patent/US10874743B2/en active Active
- 2018-12-21 IL IL304055A patent/IL304055A/en unknown
- 2018-12-21 CA CA3086763A patent/CA3086763A1/en active Pending
- 2018-12-21 WO PCT/US2018/067304 patent/WO2019133531A1/en unknown
- 2018-12-21 SG SG11202005912PA patent/SG11202005912PA/en unknown
- 2018-12-21 EP EP18894876.4A patent/EP3731869A4/en active Pending
- 2018-12-21 MX MX2020006812A patent/MX2020006812A/es unknown
- 2018-12-21 CN CN201880089841.0A patent/CN112105385A/zh active Pending
- 2018-12-21 JP JP2020535655A patent/JP2021508703A/ja active Pending
- 2018-12-21 AU AU2018396142A patent/AU2018396142A1/en active Pending
- 2018-12-21 IL IL275649A patent/IL275649B2/en unknown
-
2020
- 2020-10-16 US US17/073,019 patent/US11318205B1/en active Active
-
2022
- 2022-02-10 US US17/650,545 patent/US11723980B2/en active Active
-
2023
- 2023-04-24 US US18/305,911 patent/US20230398223A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002339A patent/JP2024038329A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112105385A (zh) | 2020-12-18 |
CA3086763A1 (en) | 2019-07-04 |
SG11202005912PA (en) | 2020-07-29 |
US10874743B2 (en) | 2020-12-29 |
IL304055A (en) | 2023-08-01 |
US11318205B1 (en) | 2022-05-03 |
EP3731869A4 (en) | 2021-09-22 |
US20230398223A1 (en) | 2023-12-14 |
IL275649B2 (en) | 2023-12-01 |
BR112020012997A2 (pt) | 2020-12-01 |
US20230106066A1 (en) | 2023-04-06 |
WO2019133531A1 (en) | 2019-07-04 |
IL275649B1 (en) | 2023-08-01 |
IL275649A (en) | 2020-08-31 |
US11723980B2 (en) | 2023-08-15 |
US20190192668A1 (en) | 2019-06-27 |
JP2021508703A (ja) | 2021-03-11 |
EP3731869A1 (en) | 2020-11-04 |
JP2024038329A (ja) | 2024-03-19 |
AU2018396142A1 (en) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
MX2022007576A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
ZA202107931B (en) | Anti-tau antibodies and methods of use | |
MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
MX2021012216A (es) | Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos. | |
EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
CR20230163A (es) | ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271) | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
WO2018081648A8 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
MX2016012530A (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. | |
MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
MX2019005322A (es) | Composiciones de recubrimiento y metodos de uso de las mismas. | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
MX2022007841A (es) | Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos. |